Zobrazeno 1 - 10
of 1 404
pro vyhledávání: '"guselkumab"'
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1240-1243 (2024)
Abstract Pityriasis Rubra Pilaris (PRP) is a rare papulosquamous inflammatory dermatosis with variable clinical presentation and poorly understood pathogenesis that often poses diagnostic and therapeutic challenges. Data on currently available treatm
Externí odkaz:
https://doaj.org/article/d183d5cb5f3f4b8f9762619fb76b644c
Autor:
April W. Armstrong, Peter Foley, Yan Liu, Megan Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Kim A. Papp, Chenglong Han
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2577-2589 (2024)
Abstract Introduction Treating plaque psoriasis (PsO) with guselkumab (GUS) promotes skin clearance and is associated with improvements in health-related quality of life (HRQoL), anxiety, and depression. It is unclear whether improvements in patient-
Externí odkaz:
https://doaj.org/article/2e1fbdbdc341498ebebba1f697824c23
Autor:
Simge Ünal, Tuğcan Yüksek
Publikováno v:
Turkderm Turkish Archives of Dermatology and Venereology, Vol 58, Iss 2, Pp 48-51 (2024)
In this case report, we present a 29-year-old patient with Down syndrome (DS) who manifested both psoriasis and hidradenitis suppurativa (HS) concurrently. The utilization of guselkumab, an interleukin 23 p19 subunit inhibitor that is approved for mo
Externí odkaz:
https://doaj.org/article/825e9e7645ae484b91ad14ef26f4ea76
Autor:
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Olivia Choi, Yevgeniy Krol, Alice B. Gottlieb
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many patients with PsA are TNFi inadequate responders (TNF-IR; either inadequate efficacy
Externí odkaz:
https://doaj.org/article/8af8899c7fd64bf9a16ff7465d160dd3
Autor:
Enzo Errichetti, Peter Wolf, Saakshi Khattri, Patricia Gorecki, Megan Miller, Jingzhi Jiang, Chenglong Han, Brian Kirby
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Mild psoriasis may be burdensome; if symptoms are inadequately controlled, switching therapy may be warranted. In the Phase 3 NAVIGATE trial, patients with moderate-to-severe plaque psoriasis received ustekinumab for 16 weeks. Patients with inadequat
Externí odkaz:
https://doaj.org/article/c88434ac983840359fa3629d2fa93948
Autor:
Andrew Blauvelt, Yanqing Chen, Patrick J. Branigan, Xuejun Liu, Samuel DePrimo, Brice E. Keyes, Monica Leung, Steven Fakharzadeh, Ya-Wen Yang, Ernesto J. Muñoz-Elías, James G. Krueger, Richard G. Langley
Publikováno v:
JID Innovations, Vol 4, Iss 5, Pp 100297- (2024)
IL-23 is a cytokine produced by myeloid cells that drives the T helper 17 pathway and plays an essential role in the pathophysiology of plaque psoriasis. IL-23 activation initiates a cascade of cytokines subsequently inducing the expression of many p
Externí odkaz:
https://doaj.org/article/3cdb3a1625bb4d1bb4480d62cb6cb130
Autor:
Andrew Blauvelt, Richard G. Langley, Patrick J. Branigan, Xuejun Liu, Yanqing Chen, Samuel DePrimo, Keying Ma, Brittney Scott, Kim Campbell, Ernesto J. Muñoz-Elías, Kim A. Papp
Publikováno v:
JID Innovations, Vol 4, Iss 5, Pp 100287- (2024)
Background: Psoriasis is an immune-mediated inflammatory disease characterized by activation of IL-23–driven IL-17–producing T cell and other IL-23 receptor–positive IL-17–producing cell responses. Selective blockade of IL-23p19 with guselkum
Externí odkaz:
https://doaj.org/article/b95df6bc33d542458a2fcbb40566670b
Autor:
Aditya Kumar Bubna, Vinayak Viplav
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 3 (2024)
Introduction: Guselkumab is an interleukin 23p19 inhibitor, and the first in this group, to be approved by the US Food and Drug Administration (FDA) for the management of moderate to severe psoriasis. Apart from its utility in psoriasis, there are a
Externí odkaz:
https://doaj.org/article/0e52cf094e1a40679fb98588fbf8de44
Autor:
Richard G. Langley, MD, Chiranjeev Sanyal, PhD, Aaron Situ, MSc, Sarah Alulis, MSc, Fareen Hassan, MSc, Steve Peterson, MPH, Rachel E. Teneralli, PhD, Jennifer Lee, MBA, Barkha P. Patel, PhD, Tim Disher, PhD
Publikováno v:
JAAD International, Vol 15, Iss , Pp 165-167 (2024)
Externí odkaz:
https://doaj.org/article/22186959faf64799ac3671ec41d4d380
Publikováno v:
Pifu-xingbing zhenliaoxue zazhi, Vol 31, Iss 3, Pp 175-179 (2024)
Objective To observe the clinical efficacy and safety of guselkumab injection in the treatment of moderate to severe plaque psoriasis. Methods Twenty three patients with moderate to severe plaque psoriasis were treated with subcutaneous injection of
Externí odkaz:
https://doaj.org/article/4912b8c5c34147afbe433015dcf59e2c